Growth Factor Receptor Agonist Combination for Neoplastic Cell Reversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neoplastic diseases, such as cancer, are invasive, costly, and often ineffective in converting neoplastic cells into non-neoplastic cells, leading to temporary suppression of proliferation or adaptation, and do not address the underlying genetic defects.
Innovation Solution
The use of pharmaceutical associations and compositions that activate growth factor receptors (GFR) and inhibit adhesion proteins to convert neoplastic cells into non-neoplastic cells, promoting self-healing and self-recovery without damaging the cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy methods are used to inhibit intracellular target proteins, then cell proliferation is suppressed, but the treatment is invasive and causes damage to healthy cells
Solution Approach 1:
Instead of using small molecule inhibitors that block intracellular targets, the patent uses growth factor receptor agonists that activate cell surface receptors to induce differentiation. This inverted approach activates endogenous protective mechanisms rather than suppressing cellular functions, thereby suppressing neoplastic proliferation while sparing healthy cells from damage.
Solution Approach 2:
The patent employs growth factor receptor agonists as intermediaries that bind to cell surface receptors and trigger intracellular signaling cascades leading to differentiation. This intermediary mechanism allows external control of cell behavior without directly introducing toxic substances into the cell, thus achieving anti-neoplastic effects while protecting healthy tissues.
2Reliability
If gene therapy is used to replace defective genes, then genetic defects can be corrected, but the treatment is complex and involves integration of foreign DNA into the genome
Solution Approach 1:
The patent extracts the essential function of gene therapy (correcting defective gene expression) but eliminates the complex DNA integration step. By using growth factor receptor agonists that activate endogenous pathways, the treatment achieves functional correction of neoplastic cells without requiring viral vectors or genomic integration, thereby simplifying the therapeutic approach.
Solution Approach 2:
The patent enables neoplastic cells to self-correct by activating their own growth factor receptors and endogenous differentiation pathways. The cells use their inherent genetic machinery to undergo differentiation and恢复正常功能, eliminating the need for external DNA delivery systems and complex integration procedures.
3Reliability
If surgery is used to extract localized neoplastic cells, then tumor mass is removed, but the procedure is invasive and may unblock dormant tumors
Solution Approach 1:
The patent replaces the mechanical approach of surgical removal with a biochemical approach using growth factor receptor agonists. The chemical therapy targets neoplastic cells specifically through receptor binding and signaling, achieving tumor suppression without the physical trauma of surgery and without the risk of mechanically unblocking dormant tumor cells.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from physical removal to biochemical modulation. By altering cell behavior through receptor activation and inducing differentiation, the treatment achieves tumor control through parameter changes in cell state rather than physical extraction, avoiding surgical complications.
4Reliability
If radiotherapy is used to treat neoplastic cells, then cell proliferation is inhibited, but the treatment causes damage to surrounding healthy tissues and has high cost
Solution Approach 1:
Instead of using ionizing radiation to damage and kill cells, the patent uses growth factor receptor agonists to activate protective and differentiation pathways. This inverted approach builds cellular defenses and promotes maturation rather than causing damage, achieving proliferation suppression while protecting healthy tissues and reducing treatment costs.
Solution Approach 2:
The patent introduces growth factor receptor agonists as intermediary molecules that mediate the therapeutic effect. These agonists selectively bind to receptors on neoplastic cells and trigger intracellular signaling that leads to differentiation, providing a targeted mechanism that spares surrounding healthy tissues from the collateral damage inherent in radiotherapy.
Data Source
AI summary
The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.